ClinicalTrials.gov
public full text
Public Domain
Exisulind Versus Placebo After Surgical Removal of the Prostate
This is a study in which patients with prostate cancer treated by surgical removal of the prostate and considered to be at risk for prostate cancer recurrence will receive Exisulind 250 mg twice a day or placebo twice a day for two years.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer#981452
- Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial#883773
- Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer#898078
- Role of Combination Therapy in Women With Refractory Overactive Bladder#906928
- A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer#887655
Record · ID 1094241
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive